Study ID: MINT
Myocardial ischemia and transfusion clinical trial
This trial is studying the use of red blood cell transfusions in hospital patients who’ve had a myocardial infarction (heart attack) and were diagnosed with anemia. Those who have blood counts less than 10 g/dL are randomized to receive either:
- liberal transfusion strategy in which patients receive a red blood cell transfusion anytime they have a blood count of less than 10 g/dL
- restrictive transfusion strategy if the blood count is below 8 g/dL and the physician believes the transfusion is in the patient’s best interest
Transfusion strategies will be maintained until the patient is discharged from the hospital (maximum of 30 days). Patients are followed for 30 days, and their vital status is confirmed at 180 days.
This multi-center randomized study seeks to determine if a liberal transfusion strategy with a threshold of 10 g/dL reduces the composite outcome of all-cause mortality or nonfatal myocardial reinfarction through 30 days following randomization vs. a restrictive transfusion strategy with a threshold of 7 to 8 g/dL among patients with acute myocardial infarction and hemoglobin concentration less than 10 g/dL.
Eligible patients must have at least one of the following:
- Symptoms of ischemia
- New or presumed new ST segment-T wave changes or new left bundle branch block
- Development of pathological Q waves
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
- Identification of an intracoronary thrombus by angiography
Patients with types I, II, 4b or type 4c MI are permitted.
- Hospitalized adult patients with hemoglobin level of less than 10 g/dL and who have had myocardial infarction
- No uncontrolled bleeding at the time of trial randomization
- No planned cardiac surgery
- No myocardial infarction immediately after cardiac surgery